Kevin Fitzgerald - Concepedia

Author

Kevin Fitzgerald

Also Known As

Fitzgerald, Kevin, K. J. FITZGERALD, K. J. FitzGerald, K. J. Fitzgerald, K.J. Fitzgerald, Kevin FitzGerald, Kevin Fitzgerald, Kevin J. FitzGerald, Kevin J. Fitzgerald, T Veale

159

Publications

21.6K

Citations

H-Index

147

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)Harvard University Massachusetts Institute of Technology Massachusetts General Hospital Brigham and Women's Hospital

About

Kevin Fitzgerald is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	38	11.7K
2	Natural Sciences	13	14	1.8K
3	Health Sciences	9	9	2.7K
4	Engineering	7	7	4.7K
5	Social Sciences	1	1	20

Kevin Fitzgerald

Publications

21.3K

Citations

H-Index

Page 1

	Year	Citations
Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape Jérôme Gilleron, William Querbes, Anja Zeigerer, Nature Biotechnology NanomedicineEngineeringEndosomal EscapeTargeted Drug DeliveryPharmaceutical Nanotechnology	2013	1.5K
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs Akin Akinc, Martin A. Maier, Muthiah Manoharan, Nature Nanotechnology NanomedicineEngineeringClinical TranslationMedicineTheranostics	2019	1.5K
Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1 David A. Guertin, Deanna M. Stevens, Carson C. Thoreen, Developmental Cell Signal TransductionSignaling PathwayCell RegulationMolecular RegulationMtorc Components Raptor	2006	1.4K
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus Alanna Strong, Maria Frank-Kamenetsky, Noemi E Lee, Nature Cholesterol LocusLipid DisorderAllelic VariantMedicineGenetics	2010	1.2K
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms Akin Akinc, William Querbes, Soma De, Molecular Therapy NanotherapeuticsEngineeringImmunologyLipid NanoparticlesMolecular Biology	2010	1.1K
Multivalent <i>N</i>-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing Jayaprakash K. Nair, Jennifer L. S. Willoughby, Amy Chan, Journal of the American Chemical Society	2014	1K
Lipid-like materials for low-dose, in vivo gene silencing Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Proceedings of the National Academy of Sciences In Vivo Gene TherapyImmunologyGene DeliveryBiomedical EngineeringTherapeutics	2010	952
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho, David Adams, Ana Silva, New England Journal of Medicine	2013	947
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 Kevin Fitzgerald, Suellen White, Anna Borodovsky, New England Journal of Medicine	2016	738
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson, Proceedings of the National Academy of Sciences	2008	635

Page 1